Novo to Present Liver Data on Wegovy and Efruxifermin at 2026 Meeting
Novo will present data at The Liver Meeting 2026. A retrospective cohort analysis compared the effectiveness of semaglutide 2.4 mg.
Related stories
Alnylam Shares Fall About 26% on Demand and Pipeline Concerns
Alnylam signaled slower-than-expected demand growth for AMVUTTRA and pushed back certain trial results, while citing near-term Medicare Advantage restrictions and proposed drug rei
M impact | EQUITY | Oct 29, 2026, 06:26 PM UTC
Alphabet Shares Fall More Than 10%, Weighing on Nasdaq
Alphabet shares fell more than 10% Thursday after quarterly earnings missed Wall Street expectations, renewing concerns about returns on AI spending. The Nasdaq 100 fell about 1.3%
M impact | EQUITY | Oct 29, 2026, 06:26 PM UTC
Caterpillar Shares Fall 7.11% to $662.63
Caterpillar shares fell 7.11% to $662.63 at 10:34 a.m. ET on October 29.
M impact | EQUITY | Oct 29, 2026, 06:26 PM UTC
Alphabet Shares Fall 13% After Earnings Disappoint Investors
Alphabet shares were recently down 13%, putting the stock on course for its worst day ever and a potential loss of about half a trillion dollars in market value.
M impact | EQUITY | Oct 29, 2026, 06:23 PM UTC
Intel Shares Fall 2.8% Ahead of Scheduled Earnings Report
Intel shares traded at $92.855, down approximately 2.80% on Oct. 29, ahead of its scheduled earnings report after the 4 p.m. ET market close.
M impact | EQUITY | Oct 29, 2026, 06:21 PM UTC
Sandisk Shares Fall 2.3% Ahead of Fiscal First-Quarter Report
Sandisk shares traded at $1,372.51, down 2.3% at 10:35 a.m. ET on October 29, ahead of its scheduled fiscal first-quarter report. The earnings call is set for 4:30 p.m. ET.
M impact | EQUITY | Oct 29, 2026, 06:21 PM UTC